Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Martin JE, Khalife-Hachem S, Grinda T, Kfoury M, Garciaz S, Pasquier F, Vargaftig J, Uzunov M, Belhabri A, Bertoli S, Cotteret S, Vergé V, Renneville A, Rosselli F, Antony-Debre I, Rouleau E, Salviat F, Caron O, Delaloge S, Pautier P, Etienne G, Recher C, Vey N, De Botton S, Leary A, Marzac C, Micol JB. Martin JE, et al. Among authors: vey n. Ann Oncol. 2021 Aug;32(8):1046-1048. doi: 10.1016/j.annonc.2021.04.015. Epub 2021 Jun 6. Ann Oncol. 2021. PMID: 34107346 Free article. No abstract available.
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M. Morschhauser F, et al. Among authors: vey n. Ann Oncol. 2012 Oct;23(10):2687-2695. doi: 10.1093/annonc/mds202. Epub 2012 Jul 5. Ann Oncol. 2012. PMID: 22767588 Free article. Clinical Trial.
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.
Rahmé R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Adès L. Rahmé R, et al. Among authors: vey n. Leukemia. 2014 Dec;28(12):2422-4. doi: 10.1038/leu.2014.240. Epub 2014 Aug 21. Leukemia. 2014. PMID: 25142818 No abstract available.
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R. Duchmann M, et al. Among authors: vey n. Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. Blood Cancer J. 2017. PMID: 28498370 Free PMC article. No abstract available.
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Largeaud L, Cornillet-Lefebvre P, Hamel JF, Dumas PY, Prade N, Dufrechou S, Plenecassagnes J, Luquet I, Blanchet O, Banos A, Béné MC, Bernard M, Bertoli S, Bonmati C, Fornecker LM, Guièze R, Haddaoui L, Hunault M, Ianotto JC, Jourdan E, Ojeda M, Peterlin P, Vey N, Zerazhi H, Yosr H, Mineur A, Cahn JY, Ifrah N, Récher C, Pigneux A, Delabesse E; French Innovative Leukemia Organization (FILO). Largeaud L, et al. Among authors: vey n. Leukemia. 2021 May;35(5):1291-1300. doi: 10.1038/s41375-020-01031-1. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32943750 Clinical Trial.
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study.
Jestin M, Tarfi S, Duchmann M, Badaoui B, Freynet N, Tran Quang V, Sloma I, Droin N, Morabito M, Leclerc M, Maury S, Fenaux P, Solary E, Selimoglu-Buet D, Wagner-Ballon O; Groupe Francophone des Myélodysplasies (GFM). Jestin M, et al. Leukemia. 2021 Mar;35(3):893-896. doi: 10.1038/s41375-020-0955-1. Epub 2020 Jul 20. Leukemia. 2021. PMID: 32684630 No abstract available.
Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.
Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, Fenaux P; European APL group. Adès L, et al. Among authors: vey n. Am J Hematol. 2013 Jul;88(7):556-9. doi: 10.1002/ajh.23451. Epub 2013 Jun 12. Am J Hematol. 2013. PMID: 23564205 Free article. Clinical Trial.
Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study.
Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J; GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK). Vey N, et al. Leukemia. 2006 Dec;20(12):2155-61. doi: 10.1038/sj.leu.2404420. Epub 2006 Oct 12. Leukemia. 2006. PMID: 17039234 Clinical Trial.
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, Gelsi-Boyer V, de Botton S, Vey N, Preudhomme C, Clavert A, Delabesse E, Park S, Birnbaum D, Fontenay M, Bernard OA, Solary E. Damm F, et al. Among authors: vey n. Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5. Leukemia. 2013. PMID: 23443343 No abstract available.
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B, Hospital MA, Zemmour C, Rey J, d'Incan E, Charbonnier A, Mohty B, Saillard C, Bonnet S, Collignon A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, Vey N. Bouchacourt B, et al. Among authors: vey n. Ann Hematol. 2020 Apr;99(4):773-780. doi: 10.1007/s00277-020-03922-w. Epub 2020 Feb 22. Ann Hematol. 2020. PMID: 32088745
399 results